Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Carcinoma, Non-Small-Cell Lung

Carcinoma

Lung Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Carcinoma, Bronchogenic

Bronchial Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Antineoplastic Agents

All Drugs and Chemicals

Camptothecin

Topoisomerase I Inhibitors

Enzyme Inhibitors

Karenitecin (BNP1350)

The purpose of this study is to determine the maximum safe dose of orally administered Karenitecin (BNP1350) in patients with solid tumors.

Initially, the safety, side effects and recommended phase 2 dose of oral Karenitecin in patients with advanced solid tumors will be determined.

When the recommended phase 2 dose has been determined, the specified dose will be used to determine if Karenitecin is effective in the treatment of patients with relapsed or refractory non-small cell lung cancer.

Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer

Phase 1 Trial of Oral Karenitecin® in Patients With Solid Tumors"

Crown Bioscience

BioNumerik Pharmaceuticals, Inc.

Nervous System Diseases

Rare Diseases

Glioma

Brain Neoplasms

Central Nervous System Neoplasms

Nervous System Neoplasms

Brain Diseases

Central Nervous System Diseases

Karenitecin 1.0 mg/m2 administered as a single 60-minute IV infusion daily for five consecutive days. The cycle is repeated every 21 days until occurrence of progressive disease or unacceptable toxicity.

The purpose of this study is to evaluate safety and efficacy ofKarenitecin (BNP1350) as a treatment of adults with brain tumors.

Study of Karenitecin (BNP1350) in Patients With Brain Tumors

Phase 2 Treatment of Adults With Primary Malignant Glioma With Karenitecin

Skin and Connective Tissue Diseases

Melanoma

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms, Nerve Tissue

Nevus, Pigmented

Nevus

Nevi and Melanomas

Skin Neoplasms

Skin Diseases

Neuroendocrine Tumor

Neuroepithelioma

Karenitecn (1.0 mg/m2) administered as a single daily 60-minute intravenous infusion for 5 consecutive days repeated every 21 days (1 treatment cycle). Patients who respond (CR\< PR, SD) can continue treatment for 6 cycles, unless unacceptable toxicity develops. Treatment will be discontinued if progressive disease or unacceptable toxicity develops.

The purpose of this study is to evaluate the safety and efficacy of Karenitecin (BNP1350) as a treatment for Malignant Melanoma.

Study of Karenitecin (BNP1350) to Treat Malignant Melanoma

Phase 2 Trial of Karenitecin (BNP1350) in Patients With Malignant Melanoma

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer	NCT00097903	Carcinoma Carcinoma, Non-...	Karenitecin (BN...	18 Years -	BioNumerik Pharmaceuticals, Inc.
Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer	NCT00097903	Carcinoma Carcinoma, Non-...	Karenitecin (BN...	18 Years -	BioNumerik Pharmaceuticals, Inc.
Study of Karenitecin (BNP1350) in Patients With Brain Tumors	NCT00062478	Brain Neoplasms Malignant Neopl... Brain Tumors	Karenitecin (BN...	18 Years -	BioNumerik Pharmaceuticals, Inc.
Study of Karenitecin (BNP1350) to Treat Malignant Melanoma	NCT00062491	Melanoma Neoplasm	Karenitecin (BN...	18 Years -	BioNumerik Pharmaceuticals, Inc.

Spots Global Cancer Trial Database for karenitecin (bnp1350)